Skip to main content

Interventional Oncology Market to Reach $2.9 billion by 2024 | Emerging Economies Offer High Growth Potential

 

According to the new market research report "Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024", published by MarketsandMarkets™, the Interventional Oncology Market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8%.

Don't miss out on business opportunities in Interventional Oncology Market

Rising preference for minimally invasive procedures, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research are some of the major factors driving the growth of this market.

The TARE/SIRT segment accounted for the largest share of the Interventional Oncology Market, by procedure, in 2018

Based on procedure, the Interventional Oncology Market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. In 2018, the TARE/SIRT procedures segment accounted for the largest market share majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents (which are used in these procedures).

Browse and in-depth TOC on "Interventional Oncology Market"

140 – Tables
33 – Figures
180 – Pages

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164

Liver cancer segment to register the highest CAGR in the Interventional Oncology Market, by application, during the forecast period

Based on cancer type, the Interventional Oncology Market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other cancers (includes pediatric cancer, prostate cancer, and breast cancer). Growth in this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities for developing advanced liver cancer therapies using interventional oncology.

North America accounted for the largest share of the Interventional Oncology Market in 2018

The Interventional Oncology Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the Interventional Oncology Market owing to factors such as the rising incidence of cancer, easy accessibility to interventional oncology, and the high adoption of technological advancements (owing to the significant per capita annual healthcare expenditure by the US government).

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=203687164

The major players operating in the Interventional Oncology Market are Medtronic (Ireland), Boston Scientific (US), BTG plc (UK), Merit Medical Systems (US), and Terumo (Japan). The other prominent players operating in the overall Interventional Oncology Market include AngioDynamics (US), Ethicon (part of J&J) (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves Medical (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), and Interface Biomaterials BV (Netherlands).

Medtronic (Ireland) dominated the global interventional oncology market in 2017. The company focuses on adopting various organic growth strategies like product launches & approvals and inorganic growth strategies, such as acquisitions and collaborations, to expand its presence and share in the interventional oncology market.

Labels:

Comments

Post a Comment

Popular posts from this blog

Best Accounting Software to Kick-start the Business for Smaller Firms – Xero

  Xero Accounting Software is an online software mainly designed for the accounting needs of small business firms. The software can be operated from a PC, phone, tablet, or Mac to view the cash flows of the company in real-time. The software is for small business houses and hence it is simple to use yet smart so that the users can devote most of the time in other important areas of their business. USP of This Software: Xero accounting software offers accounting services to small business firms in a smarter way. Some of the USPs of the software the more than 800apps integrated into the software, secure encryption, support system better performance report generation, and others apart from the basic accounting services offered. Best Accounting Software for Medium-Sized Businesses@ https://blog.360quadrants.com/2020/best-accounting-software-for-medium-sized-businesses/ Xero Pricing Xero accounting software offers 30 days of free trial after which you can choose from any of the pri...
Post a Comment
Read more

Risk-based Monitoring Software Market | Key Factor in Clinical Trial | Market Growth Worth $511 million

  Growth in the risk based monitoring software market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials. However, the high implementation cost of RBM solutions is expected to restrain the growth of this market during the forecast period. RBM Software Market Dynamics: Impact Analysis 1. Increased outsourcing of clinical trial processes to CROs 2. Cost and time efficiency of RBM solutions 3. Increasing government funding and grants to support clinical trials 4. Increased pharmaceutical R&D spending 5. Initiatives to boost digital health to propel market growth The risk-based monitoring (RBM) software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102112429 Software Component: The sof...
Post a Comment
Read more

Cell Sorting Market

The global  cell sorting market  is projected to reach USD 247.4 Million by 2021, at a CAGR of 7.0% in the forecast period (2016-2021). Factors such as technological advancements in cell sorters, rising funding and investments for development of technologically advanced cell sorters, and growing adoption of cell sorting techniques in research activities are driving the growth of global Market. The market is further driven by factors such as the growing prevalence of HIV/AIDS and cancer, expanding pharmaceutical and biotechnology industries, and launch of specific reagents for specific applications. However, factors such as the high cost of instruments and lack of awareness & technical knowledge regarding the use of cell sorters are hampering the growth of market. Geographically, the market is segmented into North America, Europe, Asia-Pacific, and RoW. Among the four geographic regions, North America is estimated to command the largest share of the market in 2016, foll...
Post a Comment
Read more